BioVersys AG (XSWX:BIOV) YoY EPS Growth: -30.22% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BIOV BioVersys AG XSWX:BIOV
2 GF Score
Price CHF28.60
View Full Analysis

What is BioVersys AG YoY EPS Growth?

BioVersys AG XSWX:BIOV +1.78% 2 YoY EPS Growth is -30.22% as of Jun. 2026. GuruFocus rates XSWX:BIOV with a GF Score™ of 2/100.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. BioVersys AG's YoY EPS Growth for the quarter that ended in Jun. 2026 was -30.22%.

BioVersys AG's Earnings per Share (Diluted) for the six months ended in Jun. 2026 was CHF-2.66.

BioVersys AG YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for BioVersys AG's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG YoY EPS Growth Chart

BioVersys AG Annual Data
Trend Dec23 Dec24 Dec25
YoY EPS Growth
- -2.29 -21.46

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25 Jun26
YoY EPS Growth - - -15.39 -29.61 -30.22
XSWX:BIOV
2GF Score
BioVersys AG XSWX:BIOV
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

BioVersys AG's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(-3.8879--3.2009)/ | -3.2009 |
=-21.46 %

BioVersys AG's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(-2.6646--2.0463)/ | -2.0463 |
=-30.22 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of -30.22% mean?
BioVersys AG (XSWX:BIOV) has a YoY EPS Growth of -30.22% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for BioVersys AG and its competitors.
Is BioVersys AG's YoY EPS Growth too high?
BioVersys AG's current YoY EPS Growth is -30.22%. Overall, BioVersys AG has a GF Score™ of 2/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's YoY EPS Growth compare to VRTX and REGN?
BioVersys AG's YoY EPS Growth of -30.22% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for BioVersys AG and its competitors. BioVersys AG's current YoY EPS Growth is -30.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current YoY EPS Growth of -30.22%. The current YoY EPS Growth is -30.22%. BioVersys AG's overall GF Score™ is 2/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current YoY EPS Growth is -30.22% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKW33:Germany
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
2GF Score

Get the complete analysis for XSWX:BIOV

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF28.60
Price